Enrasentan

DB06460ExperimentalSmall molecule

Investigated for use/treatment in congestive heart failure, chronic obstructive pulmonary disease (COPD), and benign prostatic hyperplasia.

Mechanism: Pharmacologically active on Endothelin-1 receptor and Endothelin receptor type B
Curator reviewed
Primary indication: Investigated for use/treatment in congestive heart failure, chronic obstructive pulmonary disease (COPD), and benign prostatic hyperplasia.Curator reviewed
Formula / weight: C₂₉H₃₀O₈ · 506.551 g/mol (avg)
Code names: SB-217242

Resolves to

Compound

Structure

InChIKeyGLCKXJLCYIJMRB-UPRLRBBYSA-NSMILESCCCOC1=CC=C2[C@@H]([C@H]([C@@H](C2=C1)C1=CC=C(OC)C=C1OCCO)C(O)=O)C1=CC=C2OCOC2=C1

Targets

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enrasentan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.